Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Cross-reactivity00:42

Cross-reactivity

Overview
Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

C and G are frequently mutated into T and A in coding regions of human genes.

Molecular genetics and genomics : MGG·2024
Same author

Preparation and Peculiar Magnetic Properties at Low Temperatures of La<sub>1.85</sub>Sr<sub>0.15</sub>CuO<sub>4</sub> Nanofibers.

Nanomaterials (Basel, Switzerland)·2024
Same author

Identification and Validation of Common Reference Genes for Normalization of Esophageal Squamous Cell Carcinoma Gene Expression Profiles.

BioMed research international·2022
Same author

Heterogeneity of immune control in chronic hepatitis B virus infection: Clinical implications on immunity with interferon-α treatment and retreatment.

World journal of gastroenterology·2022
Same author

Metabolomics of Esophageal Squamous Cell Carcinoma Tissues: Potential Biomarkers for Diagnosis and Promising Targets for Therapy.

BioMed research international·2022
Same author

Association of time-varying changes in physical activity with cardiac death and all-cause mortality after ICD or CRT-D implantation.

Journal of geriatric cardiology : JGC·2022

Related Experiment Video

Updated: May 16, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

Anti-HBV agents derived from botanical origin.

Li-Peng Qiu1, Ke-Ping Chen

  • 1Institute of Life Sciences, Jiangsu University, Zhenjiang, Jiangsu Province, 212013, China.

Fitoterapia
|November 21, 2012
PubMed
Summary

Botanical agents show promise for developing new hepatitis B virus (HBV) therapies. This review explores their potential as safe and effective alternatives to current treatments for chronic HBV infection.

Area of Science:

  • Hepatology
  • Pharmacology
  • Natural Products Chemistry

Background:

  • Chronic hepatitis B virus (HBV) infection affects millions globally, posing risks for liver cirrhosis and hepatocellular carcinoma (HCC).
  • Current FDA-approved therapies, including interferons and nucleos(t)ide analogues, exhibit limitations such as low specificity, side effects, and drug resistance.
  • There is a critical need for novel, effective anti-HBV drugs with improved safety profiles.

Purpose of the Study:

  • To review recent advancements in botanical agents as potential anti-HBV therapies.
  • To analyze the sources, active components, efficacy, toxicity, and mechanisms of action of botanical anti-HBV agents.
  • To evaluate the advantages and limitations of developing botanical inhibitors for chronic HBV.

Main Methods:

More Related Videos

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection
10:25

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection

Published on: February 19, 2019

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Related Experiment Videos

Last Updated: May 16, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection
10:25

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection

Published on: February 19, 2019

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

  • Literature review of research on botanical agents with anti-HBV activity.
  • Analysis of studies detailing isolation, characterization, and biological evaluation of plant-derived compounds.
  • Synthesis of information on mechanisms of action, target identification, and toxicity assessments.

Main Results:

  • Botanical agents represent a diverse and promising source for novel anti-HBV drug discovery.
  • Various plant-derived compounds demonstrate significant HBV inhibitory effects.
  • Research highlights the potential for botanical agents to offer alternative or complementary treatments for chronic HBV patients.

Conclusions:

  • Botanical agents offer a valuable resource for developing new, safe, and effective anti-HBV drugs.
  • Further research into their mechanisms and clinical application could lead to improved therapies for chronic hepatitis B.
  • Botanical derivatives may provide viable alternatives to existing treatments, addressing limitations like drug resistance.